DOCSLIB.ORG

Inherited Metabolic Disorders Involving The

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inherited Metabolic Disorders Involving The Eye (2010) 24, 507–518 & 2010 Macmillan Publishers Limited All rights reserved 0950-222X/10 $32.00 www.nature.com/eye Inherited metabolic M Rajappa, A Goyal and J Kaur REVIEW disorders involving the eye: a clinico-biochemical perspective Abstract Introduction The diagnosis of inborn errors of metabolism is challenging for most physicians. Improvements The field of inherited metabolic disorders (IMDs) in medical technology and greater knowledge of is often thought to have been born in 1902 when the human genome are resulting in significant Archibald Garrod published his first paper changes in the diagnosis, classification, and describing alkaptonuria and first coined the term treatment of inherited metabolic disorders ‘inborn error of metabolism’. Although this (IMDs). Many known inborn errors of discovery did occur in professional circles, it went 1 metabolism will be recognised earlier or treated largely unnoticed and fell into obscurity. Garrod differently because of these changes. It is recognised that some human disorders were due important that physicians recognise the clinical to enzyme deficiencies and these were because of signs of IMDs and know when to propose genetic abnormalities inherited in an autosomal advanced laboratory testing or referral to a recessive manner. These insights were virtually higher centre for better patient management. ignored for 70 years and these ideas were brought 2 Ocular manifestations occur in various to fruition by Barton Childs in 1970. metabolic disorders. Although there is an Inherited metabolic disorders are challenging extensive understanding of many inborn errors for most physicians. The number of known IMDs of metabolism at the biochemical, molecular, is probably as large as the number of presenting and metabolic levels, little is known about their symptoms that may indicate metabolic 3–5 pathogenesis. In particular, how systemic disturbances. Furthermore, physicians know metabolic disease contributes to ocular defects they may not encounter certain rare IMDs during a lifetime of practice. There is an accelerating Department of Ocular remains to be elucidated in IMDs. The Biochemistry, Dr Rajendra occurrence of eye abnormalities could be due to demographic switch from communicable Prasad Centre for direct toxic mechanisms of abnormal metabolic diseases to genetic disorders. The expression of a Ophthalmic Sciences, All products or accumulation of normal metabolites genetic disease is the combined effect of genes India Institute of Medical Sciences, New Delhi, India by errors of synthetic pathways or by deficient and the environment. There are 25 million births energy metabolism. A detailed in India annually; 0.8 million are born with congenital malformations; 0.35 million with Correspondence: J Kaur, ophthalmological assessment is essential. Department of Ocular Definitive diagnosis and management of glucose-6-phosphatase deficiency; 25 000 with Biochemistry, Dr Rajendra patients with IMDs is ideally carried out by a IMDs; 20 000 with Down’s syndrome, 15 000 with Prasad Centre for combination of specialists, including an congenital hypothyroidism; 14 000 with Ophthalmic Sciences, All India Institute of Medical ophthalmologist, paediatrician, biochemist, and thalassaemia; and 5000 with sickle cell anaemia. In India, biochemical screening of 4400 cases of Sciences, Ansari Nagar, New medical geneticist. Recent advances in the Delhi 110029, India mental retardation revealed that 5.75% (256 diagnosis and treatment of IMDs have Tel: þ 91 11 26593161; 6,7 substantially improved the prognosis for many cases) were due to various IMDs. Fax: þ 91 11 26588919. of these conditions. Inborn metabolic disorders constitute a E-mail: kaurjasbir@ rediffmail.com Eye (2010) 24, 507–518; doi:10.1038/eye.2009.229; heterogeneous group of disorders affecting the published online 2 October 2009 metabolic pathways with an underlying genetic defect. IMDs are individually rare, but Received: 17 July 2008 Accepted in revised form: Keywords: IMDs; galactosaemia; Wilson’s collectively common. IMDs are becoming 6 August 2009 disease; gyrate atrophy of the retina; screening increasingly recognised wherein early diagnosis Published online: 2 October and testing for IMDs and appropriate treatment interventions are 2009 Inborn errors of metabolism and the eye M Rajappa et al 508 mandatory to reduce the morbidity and mortality rates process in confined to the eye or as part of a systemic among the newborns.8 Early diagnosis is crucial for three disease. The age of onset of ocular abnormalities in reasons.6 First, IMDs are rapidly progressive and cause metabolic disease is variable, but onset often begins in irreversible damage early in the course of the disease. childhood, infancy, or from birth. This paper discusses Second, the treatment can often be effective, the major IMDs associated with eye abnormalities. if commenced early and long-term outcome may be Ophthalmologic manifestations occur in various improved. Lastly, correct early diagnosis helps in genetic metabolic disorders. Although there is an extensive counselling. understanding of many inborn errors of metabolism at The latest discoveries in the human genome project the metabolic, biochemical, and molecular levels, their and advances in medical technology have resulted in exact pathogenesis remains to be established. The significant alterations in the diagnosis, classification, and mechanisms by which systemic metabolic disease treatment of IMDs. These changes will aid in early contributes to ocular defects remains to be elucidated. recognition and treatment of many known IMDs. It is The various mechanisms involved could be due to direct absolutely essential that doctors diagnose IMDs early toxic mechanisms of abnormal metabolic products, and whenever necessary, refer the patient to a tertiary accumulation of normal metabolites by errors of care centre for better care, detailed laboratory workup, synthetic pathways, or by deficient energy metabolism. and management. The latest breakthroughs in the Single gene defects result in abnormalities in the diagnosis and treatment of IMDs have significantly synthesis or catabolism of proteins, carbohydrates, or fats improved the prognosis for many of these conditions.9 (Table 1). Most are due to a defect in an enzyme or transport protein, which results in a block in a metabolic pathway (Figure 1). Effects are due to toxic Eye and IMDs accumulations of substrates before the block, The eye is the fourth most common system affected by intermediates from alternative metabolic pathways, and/ genetic disease.10 More than 200 loci for genetic ocular or defects in energy production and utilisation caused by diseases have been mapped so far11,12 and the quest a deficiency of products beyond the block.13 Every continues. Hereditary eye abnormalities can either metabolic disease has several forms that vary in age of manifest as primarily isolated disorders in which disease onset, clinical severity, and often, mode of inheritance. Table 1 Classifications of inherited metabolic disorders13,14 A. Small molecule disorders B. Organelle disorders Carbohydrate metabolism Lysosomal disorders eg: Mucopolysaccharidoses, galactosaemia eg: Sphingolipidoses, glycoproteinoses, mucopolysaccharidoses, gangliosidoses (Gaucher’s disease, Niemann-Pick’s disease, Metachromatic leukodystrophy, Krabbe0s disease) Protein metabolism Mitochondrial disorders eg: Gyrate atrophy of the retina, cystinosis, Marfan’s syndrome, eg: Defects in mitochondrial b-oxidation of fatty acids, Leigh’s homocystinuria, Costeff’s optic atrophy syndrome or type III 3- disease, Alper’s disease, citric acid cycle defects, pyruvate methylglutaconic aciduria, urea cycle defects dehydrogenase deficiency, Kearns-Sayre’s syndrome, Leber’s hereditary optic neuropathy Lipid metabolism Peroxisomal disorders eg: Fish eye disease, sphingolipidoses, Zellweger’s syndrome eg: Zellweger’s syndrome, pseudo-Zellweger’s syndrome, (peroxisome biogenesis disorders), Refsum’s disease (deficiency neonatal adrenoleukodystrophy, pseudo-neonatal of phytanic acid oxidase), Bassen-Kornzweig’s syndrome adrenoleukodystrophy, rhizomelic chondrodysplasia punctata, hyperpipecolic acidaemia Nucleic acid metabolism eg: Lesch-Nyhan’s syndrome Porphyrin metabolism eg: Porphyrias Metal metabolism eg: Wilson’s disease, Menke’s disease, haemochromatosis Eye Inborn errors of metabolism and the eye M Rajappa et al 509 Environmental factors may trigger the onset and severity have a major role in diagnosis of patients with IMDs. of disease. It also depends on degree of accumulation of Hereditary diseases of the eye have symmetrical bilateral toxic substances before metabolic block, for example, involvement, as do those in metabolic disorders. Severe diet, intercurrent infection, fasting drugs, and so on. visual impairment is seen usually around 2 months of Recognition of IMDs is important as it is quite common age, when eye contact develops in most children. In fact, in incidence. The indications for metabolic studies to rule poor vision may be defective in first few weeks of life. out the possibility of IMDs are discussed in Table 2. Early Anomalies of the eye are easily recognised as in cataracts diagnosis is important, as in most cases, dietary in galactosaemia. In others as in peroxisomal diseases, restriction and early therapy prevents onset of disability. fundoscopic examination may be normal in the neonatal Prenatal diagnosis using amniocentesis and chorionic period, whereas recordings of electroretinogram (ERG) villus
Load more

Recommended publications
  • Hyperammonemia in Review: Pathophysiology, Diagnosis, and Treatment
    Pediatr Nephrol DOI 10.1007/s00467-011-1838-5 EDUCATIONAL REVIEW Hyperammonemia in review: pathophysiology, diagnosis, and treatment Ari Auron & Patrick D. Brophy Received: 23 September 2010 /Revised: 9 January 2011 /Accepted: 12 January 2011 # IPNA 2011 Abstract Ammonia is an important source of nitrogen and is the breakdown and catabolism of dietary and bodily proteins, required for amino acid synthesis. It is also necessary for respectively. In healthy individuals, amino acids that are not normal acid-base balance. When present in high concentra- needed for protein synthesis are metabolized in various tions, ammonia is toxic. Endogenous ammonia intoxication chemical pathways, with the rest of the nitrogen waste being can occur when there is impaired capacity of the body to converted to urea. Ammonia is important for normal animal excrete nitrogenous waste, as seen with congenital enzymatic acid-base balance. During exercise, ammonia is produced in deficiencies. A variety of environmental causes and medica- skeletal muscle from deamination of adenosine monophos- tions may also lead to ammonia toxicity. Hyperammonemia phate and amino acid catabolism. In the brain, the latter refers to a clinical condition associated with elevated processes plus the activity of glutamate dehydrogenase ammonia levels manifested by a variety of symptoms and mediate ammonia production. After formation of ammonium signs, including significant central nervous system (CNS) from glutamine, α-ketoglutarate, a byproduct, may be abnormalities. Appropriate and timely management requires a degraded to produce two molecules of bicarbonate, which solid understanding of the fundamental pathophysiology, are then available to buffer acids produced by dietary sources. differential diagnosis, and treatment approaches available.
    [Show full text]
  • Effect of Propionic Acid on Fatty Acid Oxidation and U Reagenesis
    Pediat. Res. 10: 683- 686 (1976) Fatty degeneration propionic acid hyperammonemia propionic acidemia liver ureagenesls Effect of Propionic Acid on Fatty Acid Oxidation and U reagenesis ALLEN M. GLASGOW(23) AND H. PET ER C HASE UniversilY of Colorado Medical Celller, B. F. SlOlillsky LaboralOries , Denver, Colorado, USA Extract phosphate-buffered salin e, harvested with a brief treatment wi th tryps in- EDTA, washed twice with ph os ph ate-buffered saline, and Propionic acid significantly inhibited "CO z production from then suspended in ph os ph ate-buffe red saline (145 m M N a, 4.15 [I-"ejpalmitate at a concentration of 10 11 M in control fibroblasts m M K, 140 m M c/, 9.36 m M PO" pH 7.4) . I n mos t cases the cells and 100 11M in methyl malonic fibroblasts. This inhibition was we re incubated in 3 ml phosph ate-bu ffered sa lin e cont aining 0.5 similar to that produced by 4-pentenoic acid. Methylmalonic acid I1Ci ll-I4Cj palm it ate (19), final concentration approximately 3 11M also inhibited ' 'C0 2 production from [V 'ejpalmitate, but only at a added in 10 II I hexane. Increasing the amount of hexane to 100 II I concentration of I mM in control cells and 5 mM in methyl malonic did not impair palmit ate ox id ation. In two experiments (Fig. 3) the cells. fibroblasts were in cub ated in 3 ml calcium-free Krebs-Ringer Propionic acid (5 mM) also inhibited ureagenesis in rat liver phosphate buffer (2) co nt ain in g 5 g/ 100 ml essent iall y fatty ac id slices when ammonia was the substrate but not with aspartate and free bovine se rum albumin (20), I mM pa lm itate, and the same citrulline as substrates.
    [Show full text]
  • List of Covered Drugs
    List of Covered Drugs Effective July 1, 2016 INTRODUCTION We are pleased to provide the 2011 Gold Coast Health Plan List of Covered Drugs as a useful reference and informational tool. The GCHP List of Covered Drugs can assist practitioners in selecting clinically appropriate and cost effective products for their patients. The information contained in the GCHP List of Covered Drugs is provided solely for the convenience of medical providers. We do not warrant or assure accuracy of such information nor is it intended to be comprehensive in nature. This List of Covered Drugs is not intended to be a substitute for the knowledge, expertise, skill and judgment of the medical provider in his or her choice of prescription drugs. All the information in this List of Covered Drugs is provided as a reference for drug therapy selection. Specific drug selection for an individual patient rests solely with the prescriber. We assume no responsibility for the actions or omissions of any medical provider based upon reliance, in whole or in part, on the information contained herein. The medical provider should consult the drug manufacturer's product literature or standard references for more detailed information. National guidelines can be found on the National Guideline Clearinghouse site at http://www.guideline.gov PREFACE The GCHP List of Covered Drugs is organized by sections. Each section is divided by therapeutic drug class primarily defined by mechanism of action. Unless exceptions are noted, generally all applicable dosage forms and strengths of the drug cited are included in the GCHP List of Covered Drugs. Generics should be considered the first line of prescribing.
    [Show full text]
  • Propionic Acidemia Information for Health Professionals
    Propionic Acidemia Information for Health Professionals Propionic acidemia is an organic acid disorder in which individuals are lacking or have reduced activity of the enzyme propionyl-CoA carboxylase, leading to propionic acidemia. Clinical Symptoms Symptoms generally begin in the first few days following birth. Metabolic crisis can occur, particularly after fasting, periods of illness/infection, high protein intake, or during periods of stress on the body. Symptoms of a metabolic crisis include lethargy, behavior changes, feeding problems, hypotonia, and vomiting. If untreated, metabolic crises can lead to tachypnea, brain swelling, cardiomyopathy, seizures, coma, basal ganglia stroke, and death. Many babies die within the first year of life. Lab findings during a metabolic crisis commonly include urine ketones, hyperammonemia, metabolic acidosis, low platelets, low white blood cells, and high blood ammonia and glycine levels. Long term effects may occur despite treatment and include developmental delay, brain damage, dystonia, failure to thrive, short stature, spasticity, pancreatitis, osteoporosis, and skin lesions. Incidence Propionic acidemia occurs in greater than 1 in 75,000 live births and is more common in Saudi Arabians and the Inuit population of Greenland. Genetics of propionic acidemia Mutations in the PCCA and PCCB genes cause propionic acidemia. Mutations prevent the production of or reduce the activity of propionyl-CoA carboxylase, which converts propionyl-CoA to methylmalonyl-CoA. This causes the body to be unable to correctly process isoleucine, valine, methionine, and threonine, resulting in an accumulation of glycine and propionic acid, which causes the symptoms seen in this condition. How do people inherit propionic acidemia? Propionic acidemia is inherited in an autosomal recessive manner.
    [Show full text]
  • Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease
    UnitedHealthcare® Commercial Medical Benefit Drug Policy Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease Policy Number: 2021D0048K Effective Date: April 1, 2021 Instructions for Use Table of Contents Page Related Commercial Policy Coverage Rationale ....................................................................... 1 • Provider Administered Drugs – Site of Care Applicable Codes .......................................................................... 3 Background.................................................................................... 3 Community Plan Policy Benefit Considerations .................................................................. 3 • Intravenous Enzyme Replacement Therapy (ERT) Clinical Evidence ........................................................................... 4 for Gaucher Disease U.S. Food and Drug Administration ............................................. 6 Centers for Medicare and Medicaid Services ............................. 6 References ..................................................................................... 7 Policy History/Revision Information ............................................. 8 Instructions for Use ....................................................................... 8 Coverage Rationale See Benefit Considerations This policy refers to the following drug products, all of which are intravenous enzyme replacement therapies used in the treatment of Gaucher disease: Cerezyme® (imiglucerase) Elelyso® (taliglucerase) VPRIV® (velaglucerase)
    [Show full text]
  • Sphingolipid Metabolism Diseases ⁎ Thomas Kolter, Konrad Sandhoff
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1758 (2006) 2057–2079 www.elsevier.com/locate/bbamem Review Sphingolipid metabolism diseases ⁎ Thomas Kolter, Konrad Sandhoff Kekulé-Institut für Organische Chemie und Biochemie der Universität, Gerhard-Domagk-Str. 1, D-53121 Bonn, Germany Received 23 December 2005; received in revised form 26 April 2006; accepted 23 May 2006 Available online 14 June 2006 Abstract Human diseases caused by alterations in the metabolism of sphingolipids or glycosphingolipids are mainly disorders of the degradation of these compounds. The sphingolipidoses are a group of monogenic inherited diseases caused by defects in the system of lysosomal sphingolipid degradation, with subsequent accumulation of non-degradable storage material in one or more organs. Most sphingolipidoses are associated with high mortality. Both, the ratio of substrate influx into the lysosomes and the reduced degradative capacity can be addressed by therapeutic approaches. In addition to symptomatic treatments, the current strategies for restoration of the reduced substrate degradation within the lysosome are enzyme replacement therapy (ERT), cell-mediated therapy (CMT) including bone marrow transplantation (BMT) and cell-mediated “cross correction”, gene therapy, and enzyme-enhancement therapy with chemical chaperones. The reduction of substrate influx into the lysosomes can be achieved by substrate reduction therapy. Patients suffering from the attenuated form (type 1) of Gaucher disease and from Fabry disease have been successfully treated with ERT. © 2006 Elsevier B.V. All rights reserved. Keywords: Ceramide; Lysosomal storage disease; Saposin; Sphingolipidose Contents 1. Sphingolipid structure, function and biosynthesis ..........................................2058 1.1.
    [Show full text]
  • The Neutral Glycosphingolipid Globotriaosylceramide Promotes Fusion Mediated by a CD4-Dependent CXCR4-Utilizing HIV Type 1 Envelope Glycoprotein
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 14435–14440, November 1998 Medical Sciences The neutral glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein ANU PURI*, PETER HUG*, KRISTINE JERNIGAN*, JOSEPH BARCHI†,HEE-YONG KIM‡,JILLON HAMILTON‡, i JOE¨LLE WIELS§,GARY J. MURRAY¶,ROSCOE O. BRADY¶, AND ROBERT BLUMENTHAL* *Section of Membrane Structure and Function, Laboratory of Experimental and Computational Biology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Frederick, MD 21702; †Laboratory of Medicinal Chemistry, Division of Basic Sciences, National Cancer Institute and ¶Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892; ‡Laboratory of Membrane Biochemistry and Biophysics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD 20852; and §Centre National de la Recherche Scientifique Unite´Mixte de Recherche 1598, Institut Gustave Roussy, Villejuif Cedex 94805, France Contributed by Roscoe O. Brady, September 25, 1998 ABSTRACT Previously, we showed that the addition of enabling individual HIV strains to choose between alternate human erythrocyte glycosphingolipids (GSLs) to nonhuman modes of entry into cells. CD41 or GSL-depleted human CD41 cells rendered those cells The GSL hypothesis is based on a number of observations, susceptible to HIV-1 envelope glycoprotein-mediated cell fu- including recovery of fusion of nonsusceptible cells after sion. Individual components in the GSL mixture were isolated transfer of protease- and heat-resistant components from by fractionation on a silica-gel column and incorporated into human erythrocytes (12, 13), physicochemical studies on the the membranes of CD41 cells.
    [Show full text]
  • Novel Insights Into the Pathophysiology of Kidney Disease in Methylmalonic Aciduria
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2017 Novel Insights into the Pathophysiology of Kidney Disease in Methylmalonic Aciduria Schumann, Anke Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-148531 Dissertation Published Version Originally published at: Schumann, Anke. Novel Insights into the Pathophysiology of Kidney Disease in Methylmalonic Aciduria. 2017, University of Zurich, Faculty of Medicine. Novel Insights into the Pathophysiology of Kidney Disease in Methylmalonic Aciduria Dissertation zur Erlangung der naturwissenschaftlichen Doktorwürde (Dr. sc. nat.) vorgelegt der Mathematisch-naturwissenschaftlichen Fakultät der Universität Zürich von Anke Schumann aus Deutschland Promotionskommission Prof. Dr. Olivier Devuyst (Vorsitz und Leitung der Dissertation) Prof. Dr. Matthias R. Baumgartner Prof. Dr. Stefan Kölker Zürich, 2017 DECLARATION I hereby declare that the presented work and results are the product of my own work. Contributions of others or sources used for explanations are acknowledged and cited as such. This work was carried out in Zurich under the supervision of Prof. Dr. O. Devuyst and Prof. Dr. M.R. Baumgartner from August 2012 to August 2016. Peer-reviewed publications presented in this work: Haarmann A, Mayr M, Kölker S, Baumgartner ER, Schnierda J, Hopfer H, Devuyst O, Baumgartner MR. Renal involvement in a patient with cobalamin A type (cblA) methylmalonic aciduria: a 42-year follow-up. Mol Genet Metab. 2013 Dec;110(4):472-6. doi: 10.1016/j.ymgme.2013.08.021. Epub 2013 Sep 17. Schumann A, Luciani A, Berquez M, Tokonami N, Debaix H, Forny P, Kölker S, Diomedi Camassei F, CB, MK, Faresse N, Hall A, Ziegler U, Baumgartner M and Devuyst O.
    [Show full text]
  • Disease Reference Book
    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................
    [Show full text]
  • Sphingolipids and Cell Signaling: Relationship Between Health and Disease in the Central Nervous System
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 6 April 2021 doi:10.20944/preprints202104.0161.v1 Review Sphingolipids and cell signaling: Relationship between health and disease in the central nervous system Andrés Felipe Leal1, Diego A. Suarez1,2, Olga Yaneth Echeverri-Peña1, Sonia Luz Albarracín3, Carlos Javier Alméciga-Díaz1*, Angela Johana Espejo-Mojica1* 1 Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá D.C., 110231, Colombia; [email protected] (A.F.L.), [email protected] (D.A.S.), [email protected] (O.Y.E.P.) 2 Faculty of Medicine, Universidad Nacional de Colombia, Bogotá D.C., Colombia; [email protected] (D.A.S.) 3 Nutrition and Biochemistry Department, Faculty of Science, Pontificia Universidad Javeriana, Bogotá D.C., Colombia; [email protected] (S.L.A.) * Correspondence: [email protected]; Tel.: +57-1-3208320 (Ext 4140) (C.J.A-D.). [email protected]; Tel.: +57-1-3208320 (Ext 4099) (A.J.E.M.) Abstract Sphingolipids are lipids derived from an 18-carbons unsaturated amino alcohol, the sphingosine. Ceramide, sphingomyelins, sphingosine-1-phosphates, gangliosides and globosides, are part of this group of lipids that participate in important cellular roles such as structural part of plasmatic and organelle membranes maintaining their function and integrity, cell signaling response, cell growth, cell cycle, cell death, inflammation, cell migration and differentiation, autophagy, angiogenesis, immune system. The metabolism of these lipids involves a broad and complex network of reactions that convert one lipid into others through different specialized enzymes. Impairment of sphingolipids metabolism has been associated with several disorders, from several lysosomal storage diseases, known as sphingolipidoses, to polygenic diseases such as diabetes and Parkinson and Alzheimer diseases.
    [Show full text]
  • Occurrence of Sulfatide As a Major Glycosphingolipid in WHHL Rabbit Serum Lipoproteins1
    J. Biochem. 102, 83-92 (1987) Occurrence of Sulfatide as a Major Glycosphingolipid in WHHL Rabbit Serum Lipoproteins1 Atsushi HARA and Tamotsu TAKETOMI Department of Lipid Biochemistry, Institute of Cardiovascular Disease , Shinshu University School of Medicine, Matsumoto , Nagano 390 Received for publication, February 12, 1987 Glycosphingolipids in serum and lipoproteins from Watanabe hereditable hyper li pidemic rabbit (WHHL rabbit), which is an animal model for human familial hypercholesterolemia (FH), were analyzed for the first time in this study . Chylo microns and very low density, low density, and high density lipoproteins contained sulfatide as a major glycosphingolipid (12nmol/ƒÊmol total phospholipids (PL) in chylomicrons, 19nmol/ƒÊmol PL in VLDL, 18nmol/ƒÊmol PL in LDL, and 14nmol/ƒÊ mol PL in HDL) with other minor glycosphingolipids such as glucosylceramide, galactosylceramide, GM3 ganglioside, lactosylceramide, and globotriaosylceramide. The concentration of sulfatide as a major glycosphingolipid in WHHL rabbit serum (121nmol/ml) was much higher than that in normal rabbit serum (3nmol/ml). Fatty acids of the sulfatides comprised mainly nonhydroxy fatty acids (C22, 23, and 24) and significant amounts of hydroxy fatty acids (about 10%), whereas long chain bases of the sulfatides comprised mostly (4E)-sphingenine with a significant amount of 4D-hydroxysphinganine (about 10%). Furthermore, sulfatides in the liver and small intestine from normal and WHHL rabbits (where serum lipoproteins are produced) were determined to amount to 260nmol/g liver in WHHL rabbit, 104 nmol/g liver in control rabbit, 99.6nmol/g small intestine in WHHL rabbit, and 31.2nmol/g small intestine in control rabbit. Ceramide portions of the sulfatides in the liver were mainly composed of (4E)-sphingenine and nonhydroxy fatty acids, while those in the small intestine were mainly composed of 4D-hydroxysphinganine and hydroxy fatty acids.
    [Show full text]
  • GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies
    International Journal of Molecular Sciences Review GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies Andrés Felipe Leal 1 , Eliana Benincore-Flórez 1, Daniela Solano-Galarza 1, Rafael Guillermo Garzón Jaramillo 1 , Olga Yaneth Echeverri-Peña 1, Diego A. Suarez 1,2, Carlos Javier Alméciga-Díaz 1,* and Angela Johana Espejo-Mojica 1,* 1 Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia; [email protected] (A.F.L.); [email protected] (E.B.-F.); [email protected] (D.S.-G.); [email protected] (R.G.G.J.); [email protected] (O.Y.E.-P.); [email protected] (D.A.S.) 2 Faculty of Medicine, Universidad Nacional de Colombia, Bogotá 110231, Colombia * Correspondence: [email protected] (C.J.A.-D.); [email protected] (A.J.E.-M.); Tel.: +57-1-3208320 (ext. 4140) (C.J.A.-D.); +57-1-3208320 (ext. 4099) (A.J.E.-M.) Received: 6 July 2020; Accepted: 7 August 2020; Published: 27 August 2020 Abstract: GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay–Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic of GM2 gangliosidoses patients that include neurodevelopment alterations, neuroinflammation, and neuronal apoptosis. Currently, there is not approved therapy for GM2 gangliosidoses, but different therapeutic strategies have been studied including hematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction therapy, pharmacological chaperones, and gene therapy.
    [Show full text]